A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
Background: Brontictuzumab is a monoclonal antibody that targets Notch1 and inhibits pathway activation. The purpose of this first-in-human study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, immunogenicity and preliminary efficacy of brontictuzumab in patients with solid tumors. Patients and methods: Subjects with selected refractory solid tumors were eligible. Brontictuzumab was administered intravenously at various dose levels and schedule during dose escalation, and at 1.5 mg/kg every 3 weeks (Q3W) during expansion. Evidence of Notch1 pathway activation as determined by an immunohistochemistry assay was required for entry in the expansion cohort. Adverse events were graded according to the NCI-CTCAE v 4.03. Efficacy was assessed by RECIST 1.1. Results: Forty-eight subjects enrolled (33 in dose escalation and 15 in the expansion phase). The MTD was 1.5 mg/kg Q3W. Dose-limiting toxicities were grade 3 diarrhea in two subjects and grade 3 fatigue in one subject. The most common drug-related adverse events of any grade were diarrhea (71%), fatigue (44%), nausea (40%), vomiting (21%), and AST increase (21%). Brontictuzumab exhibited nonlinear pharmacokinetics with dose-dependent terminal half-life ranging 1-4 days. Clinical benefit was seen in 6 of 36 (17%) assessable subjects: 2 had unconfirmed partial response (PR) and 4 subjects had prolonged (≥ 6 months) disease stabilization (SD). Both PRs and three prolonged SD occurred in adenoid cystic carcinoma (ACC) subjects with evidence of Notch1 pathway activation. Pharmacodynamic effects of brontictuzumab were seen in patients' blood and tumor. Conclusion: Brontictuzumab was well tolerated at the MTD. The main toxicity was diarrhea, an on-target effect of Notch1 inhibition. An efficacy signal was noted in subjects with ACC and Notch1 pathway activation. ClinicalTrials.gov identifier: NCT01778439.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Brontictuzumab (anti‐Notch1 receptor antibody) and Tarextumab (anti‐Notch2/3 receptor antibody) were tested in relapsed or refractory tumors, small‐cell lung cancer and pancreatic ductal adenocarcinoma, but clinical trials were discontinued owing to a low response rate in patients [145, 146, 147].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [145]
Citations
Cites
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,715 · cited 2×
“Notch1 is activated by oncogenic mutations in a variety of hematologic and epithelial tumors such as T-cell acute lymphoblastic leukemia (T-ALL) [2], breast cancer [3], and adenoid cystic carcinoma (ACC) [4].”
Backgroundvan Es, J. H., van Gijn, M. E., Riccio, O., van den Born, M., Vooijs, M., Begthel, H., Cozijnsen, M., Robine, S., Winton, D. J., Radtke, F., et al. (2005) · Nature · doi:10.1038/nature03659 · Cited by 1,543 · cited 1×
“Notch inhibition promotes differentiation of intestinal epithelial progenitors cells into secretory cells causing a mucus-producing diarrhea [9].”
BackgroundTherapeutic antibody targeting of individual Notch receptors
Wu, Y., Cain-Hom, C., Choy, L., Hagenbeek, T. J., de Leon, G. P., Chen, Y., Finkle, D., Venook, R., Wu, X., Ridgway, J., et al. (2010) · Nature · doi:10.1038/nature08878 · Cited by 720 · cited 7×
“Stoeck A, Lejnine S, Truong A et al. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.”
BackgroundInfluentialThe Varied Roles of Notch in Cancer
Aster, J. C., Pear, W. S., & Blacklow, S. C. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100127 · Cited by 710 · cited 5×
“All other NOTCH1 mutations identified in our study subjects occurred exclusively in the PEST domain (Supplementary Table S2, available at Annals of Oncology online), which is ligand-dependent (nonconstitutive) and promotes weaker Notch1 signaling [1].”
BackgroundInfluentialDomingo-Domenech, J., Vidal, S. J., Rodriguez-Bravo, V., Castillo-Martin, M., Quinn, S. A., Rodriguez-Barrueco, R., Bonal, D. M., Charytonowicz, E., Gladoun, N., de la Iglesia-Vicente, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.016 · Cited by 416
Riccio, O., van Gijn, M. E., Bezdek, A. C., Pellegrinet, L., van Es, J. H., Zimber‐Strobl, U., Strobl, L. J., Honjo, T., Clevers, H., & Radtke, F. (2008) · EMBO reports · doi:10.1038/embor.2008.7 · Cited by 410
The RUNX family: developmental regulators in cancer
Ito, Y., Bae, S.-C., & Chuang, L. S. H. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3877 · Cited by 399 · cited 1×
“The oncogenic activity of this genomic alteration is unknown, however, mutations is RUNX1 is known to be oncogenic in leukemias [15].”
BackgroundAn epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
Knoechel, B., Roderick, J. E., Williamson, K. E., Zhu, J., Lohr, J. G., Cotton, M. J., Gillespie, S. M., Fernandez, D., Ku, M., Wang, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.2913 · Cited by 367
Tolcher, A. W., Messersmith, W. A., Mikulski, S. M., Papadopoulos, K. P., Kwak, E. L., Gibbon, D. G., Patnaik, A., Falchook, G. S., Dasari, A., Shapiro, G. I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8282 · Cited by 268
Self-citationFerrarotto, R., Mitani, Y., Diao, L., Guijarro, I., Wang, J., Zweidler-McKay, P., Bell, D., William, W. N., Glisson, B. S., Wick, M. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5264 · Cited by 253 · cited 4×
“They are associated with an aggressive disease phenotype, higher incidence of liver and bone metastasis, and worse clinical outcomes [4].”
BackgroundInfluentialSelf-citationParr, C., Watkins, G., & Jiang, W. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.14.5.779 · Cited by 234 · cited 1×
“Furthermore, different Notch family members carry out distinct functions, sometimes opposing, therefore, targeting other members of the Notch family might not be of therapeutic interest [5, 6].”
BackgroundTargeting Notch signaling pathway to overcome drug resistance for cancer therapy
Wang, Z., Li, Y., Ahmad, A., Azmi, A. S., Banerjee, S., Kong, D., & Sarkar, F. H. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.06.001 · Cited by 233
Morris, L. G. T., Chandramohan, R., West, L., Zehir, A., Chakravarty, D., Pfister, D. G., Wong, R. J., Lee, N. Y., Sherman, E. J., Baxi, S. S., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1790 · Cited by 223 · cited 1×
“Activating NOTCH1 mutations occur in up to 33% of ACC patients with metastatic disease [13].”
BackgroundMessersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0607 · Cited by 218
Self-citationExpression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration
Köhler, C., Bell, A. W., Bowen, W. C., Monga, S. P., Fleig, W., & Michalopoulos, G. K. (2004) · Hepatology · doi:10.1002/hep.20156 · Cited by 196 · cited 1×
“Notch1 and Jag1 are known to be involved in hepatocytes and liver vasculature regeneration, which could be involved in the pathogenesis of the liver toxicity noted [16, 17].”
BackgroundKummar, S., O'Sullivan Coyne, G., Do, K. T., Turkbey, B., Meltzer, P. S., Polley, E., Choyke, P. L., Meehan, R., Vilimas, R., Horneffer, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.1994 · Cited by 183
Stoeck, A., Lejnine, S., Truong, A. S., Li, P., Wang, H., Zang, C., Yuan, J., Ware, C., Maclean, J. K. F., Garrett-Engele, P. W., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0830 · Cited by 151
A phase II study of RO4929097 in metastatic colorectal cancer
Strosberg, J. R., Yeatman, T., Weber, J., Coppola, D., Schell, M. J., Han, G., Almhanna, K., Kim, R., Valone, T., Jump, H., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.056 · Cited by 146
Pant, S., Jones, S. F., Kurkjian, C. D., Infante, J. R., Moore, K. N., Burris, H. A., McMeekin, D. S., Benhadji, K. A., Patel, B. K. R., Frenzel, M. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.021 · Cited by 92
Phase 2 study of RO 4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933
Lee, S. M., Moon, J., Redman, B. G., Chidiac, T. A., Flaherty, L. E., Zha, Y., Othus, M. K. D., Ribas, A., Sondak, V. K., Gajewski, T. F., et al. (2014) · Cancer · doi:10.1002/cncr.29055 · Cited by 91
Locatelli, M. A., Aftimos, P., Dees, E. C., LoRusso, P. M., Pegram, M. D., Awada, A., Huang, B., Cesari, R., Jiang, Y., Shaik, M. N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.13727 · Cited by 91
Self-citationTargeting the N otch pathway: A potential therapeutic approach for desmoid tumors
Shang, H. F., Braggio, D., Lee, Y., Sannaa, G. A. A., Creighton, C. J., Bolshakov, S. V., Lazar, A. J., Lev, D. C., & Pollock, R. E. (2015) · Cancer · doi:10.1002/cncr.29564 · Cited by 89
Zhang, X., Liu, X., Luo, J., Xiao, W. L., Ye, X., Chen, M., Li, Y., & Zhang, G.-J. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.67 · Cited by 89 · cited 1×
“Furthermore, different Notch family members carry out distinct functions, sometimes opposing, therefore, targeting other members of the Notch family might not be of therapeutic interest [5, 6].”
BackgroundDíaz-Padilla, I., Wilson, M. K., Clarke, B. A., Hirte, H. W., Welch, S. A., MacKay, H. J., Biagi, J. J., Reedijk, M., Weberpals, J. I., Fleming, G. F., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.005 · Cited by 85
Somatic mutations in the notch, NF‐KB, PIK3CA, and hedgehog pathways in human breast cancers
Jiao, X., Wood, L. D., Lindman, M., Jones, S., Buckhaults, P., Polyak, K., Sukumar, S., Carter, H., Kim, D., Karchin, R., et al. (2012) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.21935 · Cited by 85 · cited 1×
“Notch1 is activated by oncogenic mutations in a variety of hematologic and epithelial tumors such as T-cell acute lymphoblastic leukemia (T-ALL) [2], breast cancer [3], and adenoid cystic carcinoma (ACC) [4].”
BackgroundWang, L., Wang, C., Hou, L., Dou, G., Wang, Y., Hu, X., He, F., Feng, F., Zhang, H., Liang, Y., et al. (2009) · Hepatology · doi:10.1002/hep.22579 · Cited by 56
Ferrarotto, R., Duran, A., Wei, W., Carter, B. W., El‐Naggar, A. K., Su, S. Y., Bell, D., Kies, M. S., William, W. N., Glisson, B. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.6089 · Cited by 1 · cited 1×
“These ACC patients represented the entire NOTCH1 mutant population that participated in the study [4, 14].”
BackgroundSelf-citation
Cited by
Notch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
Shi, Q., Xue, C., Zeng, Y., Yuan, X., Chu, Q., Jiang, S., Wang, J., Zhang, Y., Zhu, D., & Li, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01828-x · Cited by 401
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Precision medicine for human cancers with Notch signaling dysregulation (Review)
Katoh, M., & Katoh, M. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4418 · Cited by 191
“The ORRs of monotherapy with anti-dLL4, anti-NOTcH1 and anti-NOTcH2/3 mAbs were <5% (160-165).”
Background
Metadata
- Authors
- Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L., & Munster, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of Colorado Denver (US)
- South Texas Accelerated Research Therapeutics (US)
- Yale University (US)
- OncoMed (United States) (US)
- University of California, San Francisco (US)
- Corresponding author
- Ferrarotto, R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 29
- Issue
- 7
- Pages
- 1561-1568
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2800138464
- Cited by
- 138
- References
- 28
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 26 · 2023: 26 · 2022: 20 · 2021: 16 · 2020: 10 · 2019: 11 · 2018: 1
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 480 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- OncoMed Pharmaceuticals Inc.
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Keywords
- monoclonal antibodies, solid tumors, maximum tolerated dose, pharmacokinetics, immunogenicity, diarrhea, adenoid cystic carcinoma, pharmacodynamics, refractory cancer, dose-limiting toxicity
- MeSH terms
- Antineoplastic Agents, Immunological, Adult, Aged, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasms, Prognosis, Tissue Distribution, Cohort Studies, Survival Rate, Salvage Therapy, Drug Resistance, Neoplasm, Maximum Tolerated Dose, Receptor, Notch1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.